Possible modulation of concurrent Parkinson’s disease in the management of metastatic GIST: a review of two cases
Imatinib, a tyrosine kinase inhibitor, is the mainstay of treatment for resected high-risk (adjuvant and metastatic) gastrointestinal stromal tumour (GIST) – a rare form of sarcoma. There has been recent research into the neuroprotective role and modulation of dopaminergic neurones by imatinib throu...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Royal College of Physicians of Edinburgh
2018-09-01
|
| Series: | The Journal of the Royal College of Physicians of Edinburgh |
| Subjects: | |
| Online Access: | https://www.rcpe.ac.uk/sites/default/files/jrcpe_48_3_watson-fargie.pdf |